Sucralfate

From Basic Science to the Bedside

Inbunden, Engelska, 1995

Av Daniel Hollander, Daniel Hollander, G. N. Tytgat, Guido N. Tytgat

1 459 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Finns i fler format (1)

Häftad

1 459 kr

Skickas inom 10-15 vardagar

International researchers summarize the current understanding of peptic disease and trace the development of a novel new drug for peptic disease therapy-sucralfate. Contributors present laboratory research along side data from clinical trials as well as from the practice of medicine. Articles discuss the history of sucralfate's development, mechanisms of action, clinical efficacy, and future directions for research. This volume will be of interest to scientists and clinicians working in gastroenterology and gastrointestinal physiology.

Produktinformation

Utgivningsdatum1995-01-31
Mått155 x 235 x 28 mm
Vikt781 g
FormatInbunden
SpråkEngelska
Antal sidor366
Upplaga1995
FörlagKluwer Academic Publishers Group
ISBN9780306447402

Tillhör följande kategorier

Gastroenterologi inom Medicin
Allmänmedicin inom Medicin
Klinisk medicin och internmedicin inom Medicin
Farmakologi inom Medicin
Gastrointestinal och kolorektal kirurgi inom Medicin

Pathophysiology of Peptic Ulcer Disease.- Decreased Intragastric Acid Concentration as an Approach to Peptic Disease Therapy.- General Approach to Peptic Disease Therapy.- Ulcer Healing by Strengthening of Mucosal Defense.- History of the Development of Sucralfate.- Sucralfate: A Nonsystemic Site Protective Agent.- Chemistry of Sucralfate.- Binding of Bile Acids by Sucralfate.- Mechanisms of Action of Sucralfate.- Binding of Sucralfate to the Mucosal Surface.- Stimulation of Mucus Production.- Gastroduodenal Bicarbonate Secretion and its Response to Sucralfate.- Effect of Sucrose Octasulfate on Isolated Gastric Cells.- Effect on Gastric Surfactant.- Stimulation of Mucosal Prostaglandins by Sucralfate.- Sucralfate and Helicobacter pylori.- Sucralfate and Cell Proliferation.- Vascular Factors.- Sucralfate.- Effects of Sucralfate on Growth Factor Availability.- Duodenal Ulcer Therapy, “Acid Rebound,” and Early Relapse.- Effect of Sucralfate on Experimental Ulcers.- Effect on Experimental Esophageal Injury.- Safety and Drug Interactions.- Safety of Sucralfate.- Sucralfate Drug Interaction Studies.- Sucralfate and Therapy of Peptic Disease.- Therapy of Gastric Ulcer Disease.- Therapy of Active Duodenal Ulcers.- Prevention of Ulcer Recurrence.- Therapy of Esophagitis.- Sucralfate for NSAID-Induced Gastroduodenal Lesions.- The Preventive Use of Sucralfate.- Sucralfate for Prevention of Acute Gastrointestinal Bleeding.- Prevention of Respiratory Tract Infections with Sucralfate in Ventilated ICU Patients.- Sucralfate in Nonulcer Dyspepsia, Gastritis, and Duodenitis.- Use of Sucralfate in Variceal Sclerotherapy-Induced Ulcerations.- The Clinical Role of Sucralfate in Peptic Ulcer Therapy—Comparison with H-2 Blockers and Pump Inhibitors: A Projection for the Nineties.-Future Research into the Mechanisms of Action of Sucralfate.- Future Clinical Development of Sucralfate.